STAMFORD, Conn.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Biogen (Nasdaq: BIIB), Praxis Precision Medicines ...
STAMFORD, Conn., June 05, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the first-of-its-kind patient access ...
Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing ...
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side analysts ...
Focus on Inborn Errors of Immunity expands access to exome and genome testing for the known 200,000+ patients in the US 1 impacted by these conditions and opens new opportunities for GeneDx and ...
STAMFORD, Conn.--(BUSINESS WIRE)--Sema4, a patient-centered health intelligence company, today announced the launch of Expanded Carrier Screen with Personalized Residual Risk, one of the most ...
Children who undergo expansive genetic sequencing may not be getting the thorough DNA analysis their parents were expecting, say experts at UT Southwestern Medical Center. A review of clinical tests ...
GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results